🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Crossover vs Accurate Ostial PCI for Medina 0.0.1 and 0.1.0 Left Main Bifurcation Lesions

Recruitingn/aAges 18 Years - 85 YearsAllIstanbul Mehmet Akif Ersoy Educational and Traini…
NCT07596706 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Coronary artery disease is a leading cause of mortality and morbidity globally. The left coronary artery system is critically important due to its supply of a large area of myocardium. Ostia lesions of left anterior descending artery \[LAD\] and circumflex artery \[CX\]) present technical challenges during percutaneous coronary intervention (PCI) and are considered high-risk lesions due to their anatomical location, relationship with the left main coronary artery bifurcation. Two main approaches exist for treating these lesions: accurate ostial stenting and crossover stenting extending from the left main coronary artery to the relevant branch. Accurate ostial stenting aims to avoid unnecessary stenting of the left main coronary artery, while crossover stenting is more advantageous in terms of ensuring complete coverage of the ostial region. However, the crossover approach may have disadv

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Ostial left anterior descending artery or left circumflex artery disease * Coronary intervention with second or third generation drug-eluting stent Exclusion Criteria: * Severe left main disease (≥30%, intravascular ultrasound plaque burden \>50%) * History of coronary bypass grafting * Cardiogenic shock * Left main diameter greater than stent expansion capacity (for crossover group) * In-stent restenosis * End-stage liver or kidney disease (cirrhosis, hemodialysis-dependent chronic kidney disease), * Coronary intervention with bare-metal stent * Early discontinuation or inappropriate use of DAPT treatment * Patients lost to follow-up * Patient life expectancy \<1 year (such as cancer)
💊

What it tests

  • Not listed
📍

Where

2 sites
Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Hospital
Istanbul, Turkey (Türkiye)
İstanbul Mehmet Akif Ersoy Thoracic And Cardiovascular Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy